Market Overview

Benzinga's Top Downgrades

Share:
Benzinga's Top Downgrades
Related HAE
The Daily Biotech Pulse: EyePoint Licenses Eye Inflammation Drug, Insys Strategic Review Of Opioid Assets, Neos Offering
The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs

Analysts at Benchmark downgraded Haemonetics (NYSE: HAE) from “buy” to “hold.” The target price for Haemonetics has been lowered from $49 to $46. Haemonetics shares closed at $42.54 yesterday.

Hilliard Lyons downgraded Franklin Electric Co (NASDAQ: FELE) from “buy” to “neutral.” Franklin Electric's shares closed at $45.42 yesterday.

Latest Ratings for HAE

DateFirmActionFromTo
Aug 2018Morgan StanleyMaintainsOverweightOverweight
Jun 2018JefferiesMaintainsBuyBuy
May 2018Morgan StanleyMaintainsOverweightOverweight

View More Analyst Ratings for HAE
View the Latest Analyst Ratings

Posted-In: Top DowngradesDowngrades Analyst Ratings

 

Related Articles (FELE + HAE)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
BAPItau BBAUpgrades274.0
DVNJP MorganDowngrades37.0
EOGJP MorganUpgrades118.0
EQMBarclaysDowngrades48.0
EXPDGoldman SachsDowngrades68.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

5 Basic Materials Stocks With The Highest Revenue

Wunderlich Maintains Rating on Regal Entertainment, Perceives Risks To 2014 Estimates